From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement
FROM THE EDITORS

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

 

 

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

 

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

News & Literature Highlights

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

Advertisement
Advertisement